Bosutinib for previously treated chronic myeloid leukaemia

  • Technology appraisal guidance
  • TA401
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1 Bosutinib is recommended as an option, within its marketing authorisation, for chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia in adults, when:

  • they have previously had 1 or more tyrosine kinase inhibitor and

  • imatinib, nilotinib and dasatinib are not appropriate and

  • the company provides bosutinib with the discount agreed in the patient access scheme (as revised in 2016).